Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
Sponsor: Eli Lilly and Company
Summary
The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each participant, the study will last about 35 weeks and include 3 in patient visits totaling 7 days.
Official title: A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Eloralintide on Insulin Sensitivity and Metabolism in Adult Participants With Overweight or Obesity
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
115
Start Date
2026-06
Completion Date
2027-08
Last Updated
2026-06-24
Healthy Volunteers
Yes
Conditions
Interventions
Eloralintide
Eloralintide administered SC
Placebo
Placebo administered SC
Locations (1)
Profil Institut für Stoffwechselforschung
Neuss, Germany